Commercial DNA Tests for Dogs Miss 40% of Genetic Disease Variants

Consumer genetic testing for dogs has become a $300-million industry, with companies like Embark and Wisdom Panel offering panels that test for 200-350+ genetic health conditions. Breeders use these tests to market puppies as "genetically clear" and charge premium prices. But these panels only cover known, characterized mutations -- and for most breeds, the majority of disease-causing variants have not yet been identified. A "clear" result means the dog doesn't carry the specific mutations tested, not that the dog is free of genetic disease. This matters because breeders and buyers are making breeding and purchasing decisions based on incomplete information presented as comprehensive. A breeder tests both parents with Embark, gets "clear" results on all 230+ tested conditions, and advertises the litter as "health-tested, genetically clear." The buyer pays a $3,000 premium for this assurance. But the specific form of progressive retinal atrophy or dilated cardiomyopathy in that breed line may be caused by a variant not yet in any commercial database. The gap is not theoretical. Researchers estimate that current commercial panels capture only 60% of known causal variants for canine genetic diseases, and the proportion of total genetic disease risk explained is far lower. For breeds with small populations or limited research funding, coverage can be as low as 20-30%. Cavalier King Charles Spaniels, for example, have near-universal rates of mitral valve disease and syringomyelia, but no commercial test exists for the primary genetic risk factors. This persists because the testing companies have a financial incentive to market their panels as comprehensive. Saying "we test for 350 conditions" sounds impressive, but the number of conditions tested is less important than the proportion of actual genetic risk covered for a specific breed. There is no regulatory body that validates the clinical claims of canine genetic testing companies. The FDA does not regulate animal genetic tests the way it regulates human diagnostics. The root cause is that canine genomics is decades behind human genomics in funding and research. The Canine Genome Project mapped the dog genome in 2005, but variant discovery requires large-scale studies that are expensive and slow. Most research funding goes to conditions relevant to human medicine (dogs as models for human cancer, etc.), not to conditions that only affect dogs.